Please assess the completion status of the following clinical trial:

Trial Title: GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: Patients over age 18 who are deemed eligible for transplant by their treating physician.~* Disease status:~  1. AML in ≥ 1st remission - excluding those in 1st remission with 'good risk' cytogenetic features (i.e. t(8;21), t(15;17), inv 16).~ 2. Secondary AML~ 3. ALL/LL in 1st remission with clinical or molecular features indicating a high risk for relapse; or ALL \> 2nd remission~ 4. CML failing to respond to, progressing on or not tolerating appropriate TKI therapy in first chronic phase of disease; CML in accelerated phase, second chronic phase, or in CR after accelerated phase or blast crisis.~ 5. Non-Hodgkins lymphoma with chemoresponsive disease in any of the following categories:~     1. high grade lymphomas who have failed to achieve a first CR or have relapsed following a 1st remission who are not candidates for autologous transplants or transplants requiring the use of calcineurin inhibitors.~    2. any NHL with therapy responsive disease which is considered not curable outside the transplant setting and not eligible/appropriate for autologous transplant or a higher priority protocol.~ 6. Myelodysplastic syndrome (MDS): RA/RCMD with high risk cytogenetic features or transfusion dependence, RAEB-1 and RAEB-2 and AML evolved from MDS, who are not eligible for a higher priority protocol.~ 7. Chronic myelomonocytic leukemia: CMML-1 and CMML-2, advanced polycythemia vera, and myelofibrosis.~     1. Patients must have a healthy HLA compatible (8/8 molecularly matched related, or unrelated) donor willing to undergo BM harvesting or PBSC apheresis after G-CSF administration. BM will be the preferred graft source.~    2. Patients diagnosed with any form of acute leukemia must have received induction and at least one course of consolidation chemotherapy pretransplant~* Patients must have a Karnofsky Performance Status \> 70%~* Patients will have a eGFR \<60 ml/min/1.73 m2~  1. Patients must have adequate organ function measured by: Cardiac: asymptomatic or if symptomatic then LVEF at rest must be \> 50% and must improve with exercise.~ 2. Hepatic: ALT \< 3 x ULN and total serum bilirubin \< 1.5 x ULN, unless there is congenital benign hyperbilirubinemia~ 3. Renal: eGFR \> 30 ml/min/1.73 m2~ 4. Pulmonary: asymptomatic or if symptomatic, DLCO \> 50% of predicted (corrected for hemoglobin)~* Each patient must be willing to participate as a research subject and must sign an informed consent form.~* Patient must have a fully matched related or unrelated donor willing to donate stem cells.~Exclusion Criteria:~* Major surgery or irradiation within two weeks.~* Active CNS or extramedullary malignant disease.~* Active and uncontrolled infection at time of transplantation including active infection with Aspergillus or other mold, or HIV infection~* Pregnant or lactating women - they are excluded, given the potential teratogenic effects of chemotherapy and agents used in the transplant.~* Male and female patients of child-bearing potential unwilling to use effective means of contraception~* HIV or HTLV I/II positive, hepatitis C or chronic active hepatitis B.~* Patients who have had a previous malignancy unless they are deemed by their treating physicians to be at low risk for recurrence.~* Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, follow-up and research tests.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Post Transplant Cyclophosphamide (Type: EXPERIMENTAL): Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.

Based on this trial design, predict the completion outcome and termination type (if applicable).